41
Participants
Start Date
May 7, 2024
Primary Completion Date
July 15, 2026
Study Completion Date
August 31, 2027
Dostarlimab
Dostarlimab is administered via intravenous (IV) infusion at a dose of 500 milligram (mg) for first 6 cycles (each cycle is of 21 days) followed by 1,000 mg from cycle 7 (each cycle is of 42 days)
Carboplatin
Carboplatin is administered IV at a dose of Area under the concentration time curve (AUC) 5 milligram\*millilitre/ minute (mg•mL/min) for cycles 1 to 6 (each cycle is of 21 days)
Paclitaxel
Paclitaxel is administered IV at a dose of 175 milligram per meter square (mg/m2) for cycles 1 to 6 (each cycle is of 21 days)
GSK Investigational Site, Aichi
GSK Investigational Site, Chiba
GSK Investigational Site, Ehime
GSK Investigational Site, Fukuoka
GSK Investigational Site, Fukuoka
GSK Investigational Site, Gunma
GSK Investigational Site, Hokkaido
GSK Investigational Site, Hyōgo
GSK Investigational Site, Ibaraki
GSK Investigational Site, Kanagawa
GSK Investigational Site, Numakunai
GSK Investigational Site, Okayama
GSK Investigational Site, Osaka
GSK Investigational Site, Osaka
GSK Investigational Site, Saitama
GSK Investigational Site, Shizuoka
GSK Investigational Site, Tochigi
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
Lead Sponsor
GlaxoSmithKline
INDUSTRY